MR−Based Molecular Imaging of the Brain: The Next Frontier

References

1. 1.↵
   1. Thakur M,
   2. Lentle BC

   . Report of a summit on molecular imaging. Radiology 2005; 236: 753– 55

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Weissleder R,
   2. Mahmood U

   . Molecular imaging. Radiology 2001; 219: 316– 33

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Hammoud DA,
   2. Hoffman JM,
   3. Pomper MG

   . Molecular neuroimaging: from conventional to emerging techniques. Radiology 2007; 245: 21– 42

   CrossRefPubMed
4. 4.↵
   1. Herholz K,
   2. Coope D,
   3. Jackson A

   . Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007; 6: 711– 24

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Hawkins BT,
   2. Davis TP

   . The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173– 85

   Abstract/FREE Full Text
6. 6.↵
   1. Neuwelt E,
   2. Abbott NJ,
   3. Abrey L,
   4. et al

   . Strategies to advance translational research into brain barriers. Lancet Neurol 2008; 7: 84– 96

   CrossRefPubMedWeb of Science
7. 7.↵
   1. de Boer AG,
   2. Gaillard PJ

   . Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007; 47: 323– 55

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Pardridge WM

   . Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54– 61

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Barbu E,
   2. Molnàr E,
   3. Tsibouklis J,
   4. et al

   . The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv 2009; 6: 553– 65

   CrossRefPubMed
10. 10.↵
    1. Tosi G,
    2. Costantino L,
    3. Ruozi B,
    4. et al

    . Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008; 5: 155– 74

    CrossRefPubMed
11. 11.↵
    1. Abraham MH

    . The factors that influence permeation across the blood-brain barrier. Eur J Med Chem 2004; 39: 235– 40

    CrossRefPubMed
12. 12.↵
    1. Banks WA

    . Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 2009; 9 ( suppl 1): S3

    CrossRefPubMed
13. 13.↵
    1. Broadwell RD,
    2. Salcman M,
    3. Kaplan RS

    . Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. Science 1982; 217: 164– 66

    Abstract/FREE Full Text
14. 14.↵
    1. Ohtsuki S,
    2. Terasaki T

    . Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007; 24: 1745– 58

    CrossRefPubMed
15. 15.↵
    1. Tsuji A

    . Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005; 2: 54– 62

    Abstract/FREE Full Text
16. 16.↵
    1. Reivich M,
    2. Kuhl D,
    3. Wolf A,
    4. et al

    . The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127– 37

    Abstract/FREE Full Text
17. 17.↵
    1. Kinoshita M,
    2. McDannold N,
    3. Jolesz FA,
    4. et al

    . Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 2006; 340: 1085– 90

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Bulte JW,
    2. Kraitchman DL

    . Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004; 17: 484– 99

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Cunningham CH,
    2. Arai T,
    3. Yang PC,
    4. et al

    . Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn Reson Med 2005; 53: 999– 1005

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Caravan P

    . Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006; 35: 512– 23

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Sosnovik DE,
    2. Weissleder R

    . Emerging concepts in molecular MRI. Curr Opin Biotechnol 2007; 18: 4– 10

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Querol M,
    2. Bogdanov A

    . Amplification strategies in MR imaging: activation and accumulation of sensing contrast agents (SCAs). J Magn Reson Imaging 2006; 24: 971– 82

    CrossRefPubMed
23. 23.↵
    1. Ward K,
    2. Aletras A,
    3. Balaban R

    . A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson 2000; 143: 79– 87

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Woods M,
    2. Woessner DE,
    3. Sherry AD

    . Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem Soc Rev 2006; 35: 500– 11

    CrossRefPubMed
25. 25.↵
    1. McMahon MT,
    2. Gilad AA,
    3. DeLiso MA,
    4. et al

    . New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI. Magn Reson Med 2008; 60: 803– 12

    CrossRefPubMed
26. 26.↵
    1. Higuchi M,
    2. Iwata N,
    3. Matsuba Y,
    4. et al

    . 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005; 8: 527– 33

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Ruiz-Cabello J,
    2. Walczak P,
    3. Kedziorek DA,
    4. et al

    . In vivo “hot spot” MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med 2008; 60: 1506– 11

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Ahrens ET,
    2. Flores R,
    3. Xu H,
    4. et al

    . In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005; 23: 983– 87

    CrossRefPubMedWeb of Science
29. 29.↵
    1. McCarthy JR,
    2. Weissleder R

    . Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008; 60: 1241– 51

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Kircher MF,
    2. Mahmood U,
    3. King RS,
    4. et al

    . A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63: 8122– 25

    Abstract/FREE Full Text
31. 31.↵
    1. Politi LS,
    2. Bacigaluppi M,
    3. Brambilla E,
    4. et al

    . Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. Stem Cells 2007; 25: 2583– 92

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Long CM,
    2. Bulte JW

    . In vivo tracking of cellular therapeutics using magnetic resonance imaging. Expert Opin Biol Ther 2009; 9: 293– 306

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Modo M,
    2. Cash D,
    3. Mellodew K,
    4. et al

    . Tracking transplanted stem cell migration using bifunctional, contrast agent-enhanced, magnetic resonance imaging. Neuroimage 2002; 17: 803– 11

    CrossRefPubMed
34. 34.↵
    1. Gilad AA,
    2. McMahon MT,
    3. Walczak P,
    4. et al

    . Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol 2007; 25: 217– 19. Epub 2007 Jan 28

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Hoehn M,
    2. Himmelreich U,
    3. Kruttwig K,
    4. et al

    . Molecular and cellular MR imaging: potentials and challenges for neurological applications. J Magn Reson Imaging 2008; 27: 941– 54

    CrossRefPubMed
36. 36.↵
    1. Bulte JW,
    2. Zhang S,
    3. van Gelderen P,
    4. et al

    . Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci U S A 1999; 96: 15256– 61

    Abstract/FREE Full Text
37. 37.↵
    1. Hoehn M,
    2. Wiedermann D,
    3. Justicia C,
    4. et al

    . Cell tracking using magnetic resonance imaging. J Physiol 2007; 584 ( pt 1): 25– 30. Epub 2007 Aug 9

    CrossRefPubMed
38. 38.↵
    1. Syková E,
    2. Jendelová P

    . Migration, fate and in vivo imaging of adult stem cells in the CNS. Cell Death Differ 2007; 14: 1336– 42

    CrossRefPubMed
39. 39.↵
    1. Kraitchman DL,
    2. Gilson WD,
    3. Lorenz CH

    . Stem cell therapy: MRI guidance and monitoring. J Magn Reson Imaging 2008; 27: 299– 310

    CrossRefPubMed
40. 40.↵
    1. Massoud TF,
    2. Singh A,
    3. Gambhir SS

    . Noninvasive molecular neuroimaging using reporter genes: part I, principles revisited. AJNR Am J Neuroradiol 2008; 29: 229– 34

    Abstract/FREE Full Text
41. 41.↵
    1. Gilad AA,
    2. Winnard PT,
    3. van Zijl PCM,
    4. et al

    . Developing MR reporter genes: promises and pitfalls. NMR Biomed 2007; 20: 275– 90

    CrossRefPubMedWeb of Science
42. 42.↵
    1. So PW,
    2. Parkes HG,
    3. Bell JD

    . Application of magnetic resonance methods to studies of gene therapy. Prog Nucl Magn Reson Spectr 2007; 51: 49– 62

    CrossRef
43. 43.↵
    1. Yeh E,
    2. Gustafson K,
    3. Boulianne GL

    . Green fluorescent protein as a vital marker and reporter of gene expression in Drosophila. Proc Natl Acad Sci U S A 1995; 92: 7036– 40

    Abstract/FREE Full Text
44. 44.↵
    1. Gould SJ,
    2. Subramani S

    . Firefly luciferase as a tool in molecular and cell biology. Anal Biochem 1988; 175: 5– 13

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Gilad AA,
    2. Ziv K,
    3. McMahon MT,
    4. et al

    . MRI reporter genes. J Nucl Med 2008; 49: 1905– 08

    Abstract/FREE Full Text
46. 46.↵
    1. Cohen B,
    2. Ziv K,
    3. Plaks V,
    4. et al

    . MRI detection of transcriptional regulation of gene expression in transgenic mice. Nat Med 2007; 13: 498– 503

    CrossRefPubMed
47. 47.↵
    1. Genove G,
    2. DeMarco U,
    3. Xu H,
    4. et al

    . A new transgene reporter for in vivo magnetic resonance imaging. Nat Med 2005; 11: 450– 54

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Weissleder R,
    2. Moore A,
    3. Mahmood U,
    4. et al

    . In vivo magnetic resonance imaging of transgene expression. Nat Med 2000; 6: 351– 55

    CrossRefPubMed
49. 49.↵
    1. Zurkiya O,
    2. Chan AWS,
    3. Hu X

    . MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Magn Reson Med 2008; 59: 1225– 31

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Aime S,
    2. Castelli DD,
    3. Crich SG,
    4. et al

    . Pushing the sensitivity envelope of lanthanide-based MRI contrast agents for molecular imaging applications. Acc Chem Res 2009; 42: 822– 31

    CrossRefPubMed
51. 51.↵
    1. Willinek WA,
    2. Kuhl CK

    . 3.0 T neuroimaging: technical considerations and clinical applications. Neuroimaging Clin N Am 2006; 16: 217– 28, ix

    CrossRefPubMed
52. 52.↵
    1. Trattnig S,
    2. Pinker K,
    3. Ba-Ssalamah A,
    4. et al

    . The optimal use of contrast agents at high field MRI. Eur Radiol 2006; 16: 1280– 87

    CrossRefPubMed
53. 53.↵
    1. Nakada T

    . Clinical application of high and ultra high-field MRI. Brain Dev 2007; 29: 325– 35

    CrossRefPubMed